CCL2 and breast cancer: Nevertheless, several clinical trials have shown that CCL2 concentration is only transiently suppressed after the administration of a CCL2 neutralizing antibody (CNTO 888) and that CCL2 levels might exceed pretreatment baseline levels to cause the hypermetastasis of BC cells [221,222].